磷酸化Tau蛋白用于预测心脏骤停幸存者神经功能结局
这项单中心回顾性研究纳入2016年1月至2023年6月230例心脏骤停幸存者,排除复苏前Cerebral Performance Category评分≥3者33例,最终分析197例。在自主循环恢复(ROSC)后24小时内检测血浆p-Tau(酶联免疫吸附法)、记录舒张压(DBP)并计算脑CT灰白质比(GWR)。出院时Cerebral Performance Category评分1-2为良好结局,54例(27.4%)为良好结局。回归分析显示p-Tau水平越高神经功能结局越差;p-Tau区分神经功能结局的最佳截断值为456 pg/mL,AUC 0.71;p-Tau联合GWR和DBP后AUC提升至0.80(vs 0.71,p=0.008)。作者认为ROSC后24小时内血浆p-Tau尤其联合GWR和DBP可能作为心脏骤停幸存者神经功能结局的生物标志物。
要点
- ROSC后24小时内血浆p-Tau区分出院神经功能结局(Cerebral Performance Category 1-2为良好)的最佳截断值为456 pg/mL,AUC 0.71。
- p-Tau联合GWR和DBP预测神经功能结局的AUC为0.80,高于单用p-Tau的0.71(p=0.008)。
- 197例中54例(27.4%)出院时神经功能结局良好;p-Tau水平越高,神经功能结局越差。
- p-Tau水平与ROSC后舒张压(DBP)及脑CT灰白质比(GWR)显著相关。
适用人群与场景
- 心脏骤停幸存者,于2016年1月至2023年6月纳入单中心回顾性研究,共230例,排除复苏前Cerebral Performance Category评分≥3者33例,最终分析197例。
- 血浆和脑CT均在ROSC后24小时内采集。
诊断标准与关键阈值
- 出院时Cerebral Performance Category评分1-2定义为神经功能良好结局。
- p-Tau区分神经功能结局的最佳截断值为456 pg/mL。
研究设计与关键结果
- 单中心回顾性研究,197例心脏骤停幸存者,54例(27.4%)出院时神经功能结局良好。
- 回归分析显示较高的p-Tau水平与神经功能不良结局相关。
- p-Tau水平与ROSC后舒张压(DBP)及脑CT灰白质比(GWR)显著相关。
- p-Tau区分神经功能结局的最佳截断值为456 pg/mL,AUC为0.71。
- p-Tau联合GWR和DBP预测神经功能结局的AUC为0.80,高于单用p-Tau的0.71(p=0.008)。
证据类型、等级与局限
- 证据类型:单中心回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,ROSC后24小时内测量的血浆p-Tau水平,尤其联合GWR和DBP,可能作为心脏骤停幸存者神经功能结局的生物标志物,较高水平预测不良结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Phosphorylated Tau (p-Tau), an early biomarker of neuronal damage, has emerged as a promising candidate for predicting neurological outcomes in cardiac arrest (CA) survivors. Despite its potential, the correlation of p-Tau with other clinical indicators remains underexplored. This study assesses the predictive capability of p-Tau and its effectiveness when used in conjunction with other predictors.
METHODS: In this single-center retrospective study, 230 CA survivors had plasma and brain computed tomography scans collected within 24 h after the return of spontaneous circulation (ROSC) from January 2016 to June 2023. The patients with prearrest Cerebral Performance Category scores ≥ 3 were excluded (n = 33). The neurological outcomes at discharge with Cerebral Performance Category scores 1-2 indicated favorable outcomes. Plasma p-Tau levels were measured using an enzyme-linked immunosorbent assay, diastolic blood pressure (DBP) was recorded after ROSC, and the gray-to-white matter ratio (GWR) was calculated from brain computed tomography scans within 24 h after ROSC.
RESULTS: Of 197 patients enrolled in the study, 54 (27.4%) had favorable outcomes. Regression analysis showed that higher p-Tau levels correlated with unfavorable neurological outcomes. The levels of p-Tau were significantly correlated with DBP and GWR. For p-Tau to differentiate between neurological outcomes, an optimal cutoff of 456 pg/mL yielded an area under the receiver operating characteristic curve of 0.71. Combining p-Tau, GWR, and DBP improved predictive accuracy (area under the receiver operating characteristic curve = 0.80 vs. 0.71, p = 0.008).
CONCLUSIONS: Plasma p-Tau levels measured within 24 h following ROSC, particularly when combined with GWR and DBP, may serve as a promising biomarker of neurological outcomes in CA survivors, with higher levels predicting unfavorable outcomes.
参考来源
- Huang SS, Huang CH, Hsu NT, et al. Application of Phosphorylated Tau for Predicting Outcomes Among Sudden Cardiac Arrest Survivors. Neurocrit Care. 2024. PMID: 38982004. doi:10.1007/s12028-024-02055-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。